A Retrospective Analysis of the Therapeutic Outcomes of 117 Neuroblastoma Patients Treated at a Single Pediatric Oncology Center in China
Objective Recent therapeutic advances have greatly enhanced the survival rates of patients with neuroblastoma (NB). However, the outcomes of neuroblastoma patients in China, particularly those with high-risk (HR) NB, remain limited. Method We retrospectively analyzed the clinical data and outcomes o...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-06-01
|
| Series: | Cancer Control |
| Online Access: | https://doi.org/10.1177/10732748231187837 |
| _version_ | 1827767552680394752 |
|---|---|
| author | Uet Yu MMed (Hons), PhD Huanli Xu MMed Senmin Chen MD Meng Yi MMed Chao Liu MMed Xiaoling Zhang MD Chunjing Wang MMed Jianming Song MD Yungen Gan BMed Jianyao Wang MD Yuanxiang Wang MMed Qing Zhang MMed Junjie Sun MD Bei Xia BMed Gongwei Zhang MMed Changgang Li BMed Feiqiu Wen MD, PhD Sixi Liu MD Xiuli Yuan MD |
| author_facet | Uet Yu MMed (Hons), PhD Huanli Xu MMed Senmin Chen MD Meng Yi MMed Chao Liu MMed Xiaoling Zhang MD Chunjing Wang MMed Jianming Song MD Yungen Gan BMed Jianyao Wang MD Yuanxiang Wang MMed Qing Zhang MMed Junjie Sun MD Bei Xia BMed Gongwei Zhang MMed Changgang Li BMed Feiqiu Wen MD, PhD Sixi Liu MD Xiuli Yuan MD |
| author_sort | Uet Yu MMed (Hons), PhD |
| collection | DOAJ |
| description | Objective Recent therapeutic advances have greatly enhanced the survival rates of patients with neuroblastoma (NB). However, the outcomes of neuroblastoma patients in China, particularly those with high-risk (HR) NB, remain limited. Method We retrospectively analyzed the clinical data and outcomes of NB patients who were treated at a tertiary pediatric cancer facility in China between January 2013 and October 2021. Results A total of 117 NB patients were recruited. Patients with very low-risk (VLR), low-risk (LR), intermediate-risk (IR), and HR-NB patients made up 4%, 27%, 15%, and 54% of total patient population, respectively. Patients diagnosed between 2013 and 2018 were treated according to the protocol of Sun Yat-Sen University Cancer Center and those diagnosed between 2019 and 2021 were treated according to the COG ANBL0531 or ANBL0532 protocol with or without autologous stem cell transplantation (ASCT). The 5-year EFS and OS of all risk groups of patients were 67.29% and 77.90%, respectively. EFS and OS were significantly decreased in patients with higher risk classifications (EFS: VLR/LR vs IR vs HR: 97.22% vs 67.28% vs 51.83%; ***P = .001; OS: VLR/LR vs IR vs HR: 97.06% vs 94.12% vs 64.38%; *P = .046). In HR-NB patients treated according to the COG protocol between 2019 and 2021, the 3-year OS of patients who received tandem ASCT was significantly greater than those who did not receive ASCT (93.33% % vs 47.41%; *P = .046; log-rank test). EFS was not significantly different between patients with and without ASCT (72.16% vs 60.32%). Conclusion Our findings show that patients with lower risk classification have a positive prognosis for survival. The prognosis of patients with HR-NB remains in need of improvement. ASCT may enhance OS in HR-NB patients; however, protocol adjustment may be necessary to increase EFS in these patients. |
| first_indexed | 2024-03-11T12:01:02Z |
| format | Article |
| id | doaj.art-b89ad73822a2459692a799afeeff569e |
| institution | Directory Open Access Journal |
| issn | 1526-2359 |
| language | English |
| last_indexed | 2024-03-11T12:01:02Z |
| publishDate | 2023-06-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Cancer Control |
| spelling | doaj.art-b89ad73822a2459692a799afeeff569e2023-11-08T06:33:22ZengSAGE PublishingCancer Control1526-23592023-06-013010.1177/10732748231187837A Retrospective Analysis of the Therapeutic Outcomes of 117 Neuroblastoma Patients Treated at a Single Pediatric Oncology Center in ChinaUet Yu MMed (Hons), PhDHuanli Xu MMedSenmin Chen MDMeng Yi MMedChao Liu MMedXiaoling Zhang MDChunjing Wang MMedJianming Song MDYungen Gan BMedJianyao Wang MDYuanxiang Wang MMedQing Zhang MMedJunjie Sun MDBei Xia BMedGongwei Zhang MMedChanggang Li BMedFeiqiu Wen MD, PhDSixi Liu MDXiuli Yuan MDObjective Recent therapeutic advances have greatly enhanced the survival rates of patients with neuroblastoma (NB). However, the outcomes of neuroblastoma patients in China, particularly those with high-risk (HR) NB, remain limited. Method We retrospectively analyzed the clinical data and outcomes of NB patients who were treated at a tertiary pediatric cancer facility in China between January 2013 and October 2021. Results A total of 117 NB patients were recruited. Patients with very low-risk (VLR), low-risk (LR), intermediate-risk (IR), and HR-NB patients made up 4%, 27%, 15%, and 54% of total patient population, respectively. Patients diagnosed between 2013 and 2018 were treated according to the protocol of Sun Yat-Sen University Cancer Center and those diagnosed between 2019 and 2021 were treated according to the COG ANBL0531 or ANBL0532 protocol with or without autologous stem cell transplantation (ASCT). The 5-year EFS and OS of all risk groups of patients were 67.29% and 77.90%, respectively. EFS and OS were significantly decreased in patients with higher risk classifications (EFS: VLR/LR vs IR vs HR: 97.22% vs 67.28% vs 51.83%; ***P = .001; OS: VLR/LR vs IR vs HR: 97.06% vs 94.12% vs 64.38%; *P = .046). In HR-NB patients treated according to the COG protocol between 2019 and 2021, the 3-year OS of patients who received tandem ASCT was significantly greater than those who did not receive ASCT (93.33% % vs 47.41%; *P = .046; log-rank test). EFS was not significantly different between patients with and without ASCT (72.16% vs 60.32%). Conclusion Our findings show that patients with lower risk classification have a positive prognosis for survival. The prognosis of patients with HR-NB remains in need of improvement. ASCT may enhance OS in HR-NB patients; however, protocol adjustment may be necessary to increase EFS in these patients.https://doi.org/10.1177/10732748231187837 |
| spellingShingle | Uet Yu MMed (Hons), PhD Huanli Xu MMed Senmin Chen MD Meng Yi MMed Chao Liu MMed Xiaoling Zhang MD Chunjing Wang MMed Jianming Song MD Yungen Gan BMed Jianyao Wang MD Yuanxiang Wang MMed Qing Zhang MMed Junjie Sun MD Bei Xia BMed Gongwei Zhang MMed Changgang Li BMed Feiqiu Wen MD, PhD Sixi Liu MD Xiuli Yuan MD A Retrospective Analysis of the Therapeutic Outcomes of 117 Neuroblastoma Patients Treated at a Single Pediatric Oncology Center in China Cancer Control |
| title | A Retrospective Analysis of the Therapeutic Outcomes of 117 Neuroblastoma Patients Treated at a Single Pediatric Oncology Center in China |
| title_full | A Retrospective Analysis of the Therapeutic Outcomes of 117 Neuroblastoma Patients Treated at a Single Pediatric Oncology Center in China |
| title_fullStr | A Retrospective Analysis of the Therapeutic Outcomes of 117 Neuroblastoma Patients Treated at a Single Pediatric Oncology Center in China |
| title_full_unstemmed | A Retrospective Analysis of the Therapeutic Outcomes of 117 Neuroblastoma Patients Treated at a Single Pediatric Oncology Center in China |
| title_short | A Retrospective Analysis of the Therapeutic Outcomes of 117 Neuroblastoma Patients Treated at a Single Pediatric Oncology Center in China |
| title_sort | retrospective analysis of the therapeutic outcomes of 117 neuroblastoma patients treated at a single pediatric oncology center in china |
| url | https://doi.org/10.1177/10732748231187837 |
| work_keys_str_mv | AT uetyummedhonsphd aretrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT huanlixummed aretrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT senminchenmd aretrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT mengyimmed aretrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT chaoliummed aretrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT xiaolingzhangmd aretrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT chunjingwangmmed aretrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT jianmingsongmd aretrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT yungenganbmed aretrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT jianyaowangmd aretrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT yuanxiangwangmmed aretrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT qingzhangmmed aretrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT junjiesunmd aretrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT beixiabmed aretrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT gongweizhangmmed aretrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT changganglibmed aretrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT feiqiuwenmdphd aretrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT sixiliumd aretrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT xiuliyuanmd aretrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT uetyummedhonsphd retrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT huanlixummed retrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT senminchenmd retrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT mengyimmed retrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT chaoliummed retrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT xiaolingzhangmd retrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT chunjingwangmmed retrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT jianmingsongmd retrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT yungenganbmed retrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT jianyaowangmd retrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT yuanxiangwangmmed retrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT qingzhangmmed retrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT junjiesunmd retrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT beixiabmed retrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT gongweizhangmmed retrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT changganglibmed retrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT feiqiuwenmdphd retrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT sixiliumd retrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina AT xiuliyuanmd retrospectiveanalysisofthetherapeuticoutcomesof117neuroblastomapatientstreatedatasinglepediatriconcologycenterinchina |